MDS is a bone marrow failure disorder
MDS is a blood cancer
Learn More >
Season 1: Episode 4:

Do Immune Check Inhibitors have a Role in the Treatment of Higher-Risk MDS?

Dr. Howard S. Oster

This podcast will discuss the combination of azacitidine and pembrolizumab in patients with higher-risk MDS, a personalized prediction model based on clinical and genomic data, the classification of therapy-related MDS as well as the importance of platelet counts as a prognostic factor.


  • Azacitidine with Pembrolizumab in Intermediate-1 or Higher-Risk MDS
  • Personalized Prediction Model in MDS
  • Therapy-Related MDS Deserves Specific Sub-classification
  • Influence of Platelet Count on Prognosis in MD





If you have questions or feedback on this podcast, please feel free to contact us. We would love to hear from you!

Contact Us

Enjoying Our Podcasts?

If you are enjoying our podcasts and other resources, please consider becoming a Professional Member of the MDS Foundation.

Learn More About Membership
Review answers to commonly asked questions or get answers to your questions from an MDS expert